New Castle, DE —May 13, 2025 — ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biorepository services for the global pharmaceutical and biotechnology industry, today announced the appointment of two accomplished industry leaders, Martin LeBlanc and Greg Swanberg, to its Board of Directors.
Other board members include executive chair John Chickosky, and directors Charles Saller, Ph.D. (ABS Bio founder and CEO), Adam Dolder (3 Boomerang Capital) and Logan Stinson (3 Boomerang Capital).
“We are pleased to welcome Martin and Greg to the ABS Bio Board,” said John Chickosky, executive chairman of ABS Bio. “They both bring deep experience in laboratory services for the global pharma and biopharmaceutical industry that will be invaluable to ABS as we grow our business and pursue our mission to power the discovery of new drugs and diagnostics.”
MARTIN LEBLANC
Martin is co-founder and was named Vice-Chairman of CellCarta Biosciences in 2023 after having served as CEO from 2007 to 2023 and COO from 2000 to 2007. Formerly known as Caprion Biosciences and headquartered in Montreal, Canada, CellCarta is a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry. CellCarta operates globally with over 1000 employees in its 9 facilities located in Canada, the United States, Belgium, Australia and China. Under Martin’s leadership the company sustained strong organic revenue and profitability growth, concluded 10 company mergers and acquisitions, and has been managed under the successive ownership of 4 leading healthcare private equity firms: Great Point Partners LLP (2007-12), Chicago Growth Partners LLP (2012-16), GHO Capital (2016-19), and Arsenal Capital Partners (2019-present). He serves as chairman of the board of directors of Icentia, and Saguaro Biosciences as well as a member of the board of directors of Sygnature Discovery, IXCells Biotechnologies, ABS and Montreal In-Vivo. Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.
GREG SWANBERG
Greg is currently CEO of Core Biosample Solutions and Founder and Chairman of Core UCO Systems. He was previously CEO of BioStorage Technologies (now Azenta). He has extensive operational and leadership experience of over 40 years in executive roles. His focus has centered on the outsourcing of critical technical operations for highly regulated industries such as Pharma/Bio research and manufacturing facilities, hospitals, data centers and nuclear power and weapons facilities. His involvement has ranged from serving as a major buyer of such services to consulting and advising pharma and bio companies in the development of outsourcing documentation and leading competitive bidding processes for corporations acquiring these services. For the last 15 years, his work has specifically centered on life science centered biorepository and associated sample management related services. Prior to joining the ABS Board, Greg has been closely engaged with ABS leadership in a variety of advisory roles including serving as a member of the company’s Industry Advisory Board.
